Serum hepatocyte growth factor levels in 106 patients with Hodgkin disease at diagnosis according to patient clinical and laboratory features
| Patients . | Serum HGF, pg/mL . | ||||
|---|---|---|---|---|---|
| Features . | n . | Mean ± SEM . | Median . | Range . | P4-150 . |
| Sex | |||||
| Male | 67 | 1374 ± 114 | 1179 | 350 -4925 | .5 |
| Female | 39 | 1453 ± 156 | 1350 | 338 -5800 | |
| Age | |||||
| ≥40 y | 37 | 1414 ± 149 | 1210 | 352 -4925 | .8 |
| <40 yr | 69 | 1397 ± 117 | 1190 | 338 -5800 | |
| Stages | |||||
| I-II | 60 | 1259 ± 102 | 1068 | 350 -4190 | .1 |
| III-IV | 46 | 1591 ± 161 | 1293 | 338 -5800 | |
| Stage A | 50 | 1032 ± 88 | 874 | 338 -3186 | <.0001 |
| Stage B | 56 | 1734 ± 141 | 1623 | 350 -5800 | |
| Bulky | 33 | 1344 ± 150 | 1420 | 401 -4190 | .1 |
| Nonbulky | 73 | 1344 ± 114 | 1150 | 338 -5800 | |
| Histological subtype | |||||
| LR + NS I | 53 | 1282 ± 130 | 1150 | 395 -5800 | .8 |
| NS II + MC + LD | 40 | 1282 ± 128 | 1150 | 350 -4190 | |
| Hb, g/L | |||||
| ≥100.5 | 86 | 1293 ± 93 | 1046 | 338 -4925 | .007 |
| <100.5 | 19 | 1898 ± 267 | 1559 | 400 -5800 | |
| Albumin, g/L | |||||
| ≥40 | 80 | 1300 ± 97 | 1108 | 350 -4925 | .09 |
| <40 | 16 | 1801 ± 325 | 1500 | 400 -5800 | |
| ESR | |||||
| Elevated | 75 | 1586 ± 117 | 1420 | 338 -5800 | .0002 |
| Nonelevated | 25 | 841 ± 74 | 730 | 352 -1700 | |
| Patients . | Serum HGF, pg/mL . | ||||
|---|---|---|---|---|---|
| Features . | n . | Mean ± SEM . | Median . | Range . | P4-150 . |
| Sex | |||||
| Male | 67 | 1374 ± 114 | 1179 | 350 -4925 | .5 |
| Female | 39 | 1453 ± 156 | 1350 | 338 -5800 | |
| Age | |||||
| ≥40 y | 37 | 1414 ± 149 | 1210 | 352 -4925 | .8 |
| <40 yr | 69 | 1397 ± 117 | 1190 | 338 -5800 | |
| Stages | |||||
| I-II | 60 | 1259 ± 102 | 1068 | 350 -4190 | .1 |
| III-IV | 46 | 1591 ± 161 | 1293 | 338 -5800 | |
| Stage A | 50 | 1032 ± 88 | 874 | 338 -3186 | <.0001 |
| Stage B | 56 | 1734 ± 141 | 1623 | 350 -5800 | |
| Bulky | 33 | 1344 ± 150 | 1420 | 401 -4190 | .1 |
| Nonbulky | 73 | 1344 ± 114 | 1150 | 338 -5800 | |
| Histological subtype | |||||
| LR + NS I | 53 | 1282 ± 130 | 1150 | 395 -5800 | .8 |
| NS II + MC + LD | 40 | 1282 ± 128 | 1150 | 350 -4190 | |
| Hb, g/L | |||||
| ≥100.5 | 86 | 1293 ± 93 | 1046 | 338 -4925 | .007 |
| <100.5 | 19 | 1898 ± 267 | 1559 | 400 -5800 | |
| Albumin, g/L | |||||
| ≥40 | 80 | 1300 ± 97 | 1108 | 350 -4925 | .09 |
| <40 | 16 | 1801 ± 325 | 1500 | 400 -5800 | |
| ESR | |||||
| Elevated | 75 | 1586 ± 117 | 1420 | 338 -5800 | .0002 |
| Nonelevated | 25 | 841 ± 74 | 730 | 352 -1700 | |
In Stage B, low Hb levels and elevated ESR are associated with higher serum HGF levels.
HGF indicates hepatocyte growth factor; Hb, hemoglobin; ESR, erythrocyte sedimentation ratio; see Table 1 for other abbreviations.
P value is based on the univariate analysis performed by the Mann-Whitney test.